Long-time Chairman to retire AUSTIN, Texas , Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced the retirement of its Chairman, G. Walter Loewenbaum , from its Board of Directors ("Board") effective August 3, 2020 . "On behalf of Luminex's shareholders and Board, I
Delivers Accelerated Organic Growth and Profitability AUSTIN, Texas , Aug. 4, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its second quarter ended June 30, 2020 . All amounts in this release are in conformity with U.S.
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season AUSTIN, Texas , July 22, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an EUA request to the FDA for a new expanded version of its
AUSTIN, Texas , July 20, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the second quarter ended June 30, 2020 on Tuesday, August 4, 2020 . A press release announcing the results is scheduled for release after the close of trading on that
- xMAP SARS-CoV-2 Multi-Antigen IgG Assay is enabled by xMAP Technology, the gold standard for multiplexing serologic testing - Antibody test detects previous COVID-19 infection with high specificity and high sensitivity in clinical studies, delivering comprehensive, accurate results while
Second Quarter Earnings Call Scheduled for August 3, 2020 AUSTIN, Texas , July 8, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced 2 nd quarter 2020 revenues of between $109 and $110 million , up more than 30% over the 2 nd quarter of 2019.
- Luminex begins rollout of next generation of xMAP® Technology, the gold standard for multiplexing of biological tests - New xMAP® INTELLIFLEX System enables its Life Science Research Partners and customers to explore new applications, including offering a unique ability to simultaneously detect
- Assay uses multiplexing for highly specific and sensitive detection of IgG antibodies against SARS-CoV-2 - Assay runs on all xMAP® platforms, the gold standard for multiplex serological testing, and detects previous infection and potential immunity to SARS-CoV-2 - Company plans to launch
AUSTIN, Texas , May 22, 2020 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2020 of $0.09 per share of common stock payable on July 9, 2020 to stockholders of record as of the close
AUSTIN, Texas , May 8, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) (" Luminex ") announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement pursuant to Section